Default Theme

Inhibitors of Protein Kinases and Protein Phosphates [electronic resource] / edited by Lorenzo A. Pinna, Patricia T.W. Cohen.

Call Number	615
Title	Inhibitors of Protein Kinases and Protein Phosphates edited by Lorenzo A. Pinna, Patricia T.W. Cohen. with contributions by numerous experts
Physical Description	X, 458 p. online resource.
Series	Handbook of Experimental Pharmacology, 0171-2004 ; 167
Contents	Protein Kinase Inhibitors for the Treatment of Disease: The Promise and the Problems -- General Aspects of PKs Inhibition -- New Design Strategies for Ligands That Target Protein Kinase-Mediated Protein-Protein Interactions -- Pharmacological Potential and Inhibitors of Individual Classes of Protein Kinases -- The Paullones: A Family of Pharmacological Inhibitors of Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3 -- Pharmacological Potential of p38 MAPK Inhibitors -- Inhibitors of PKA and Related Protein Kinases -- Inhibitors of Protein Kinase CK2: Structural Aspects -- Aminoglycoside Kinases and Antibiotic Resistance -- Pharmacological Potential and Inhibitors of Individual Classes of Protein Phosphatases -- Protein Tyrosine Phosphatases as Therapeutic Targets -- Structure-Based Design of Protein Tyrosine Phosphatase Inhibitors -- Biological Validation of the CD45 Tyrosine Phosphatase as a Pharmaceutical Target -- Serine/Threonine Protein Phosphatase Inhibitors with Antitumor Activity -- Inhibitors in Clinical Use or Advanced Clinical Trials -- Clinical Immunosuppression using the Calcineurin-Inhibitors Ciclosporin and Tacrolimus -- Targeted Therapy with Imatinib: An Exception or a Rule? -- Clinical Aspects of Imatinib Therapy -- Isoquinolinesulfonamide: A Specific Inhibitor of Rho-Kinase and the Clinical Aspect of Anti-Rho-Kinase Therapy -- Discovery and Development of Iressa: The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase.
Summary	The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkable achievements in the field and to illustrate how beneficial these studies can be for the advancement of both basic knowledge on biological regulation and deregulation and for the clinical treatment of a wide spectrum of diseases. This goal is attained by contributions of leader investigators in the field, who address the issue from different angles.
Added Author	Pinna, Lorenzo A. editor. Cohen, Patricia T.W. editor. SpringerLink (Online service)
Subject	MEDICINE. PHARMACOLOGY. ONCOLOGY. MEDICAL BIOCHEMISTRY. PATHOLOGY. Biomedicine. Pharmacology/Toxicology. Oncology. Pathology. Medical Biochemistry.
Multimedia	http://dx.doi.org/10.1007/b137900

Libraries with this item

950	Biomedical and Life Sciences (Springer-11642)

Total Ratings: 0

Copies
MARC Record
Reviews
Details


No records found to display.

03859nam a22005535i 4500

001

vtls001568656

003

VRT

005

20170831184300.0

007

cr nn 008mamaa

008

170831s2005 gw | s |||| 0|eng d

020

$a 9783540266709 $9 978-3-540-26670-9

024

$a 10.1007/b137900 $2 doi

035

$a (DE-He213)978-3-540-26670-9

039

$y 201708311843 $z santha

050

$a RM1-950

072

$a MMG $2 bicssc

072

$a MED071000 $2 bisacsh

082

$a 615 $2 23

245

$a Inhibitors of Protein Kinases and Protein Phosphates $h [electronic resource] / $c edited by Lorenzo A. Pinna, Patricia T.W. Cohen.

246

$a with contributions by numerous experts

264

$a Berlin, Heidelberg : $b Springer Berlin Heidelberg, $c 2005.

300

$a X, 458 p. $b online resource.

336

$a text $b txt $2 rdacontent

337

$a computer $b c $2 rdamedia

338

$a online resource $b cr $2 rdacarrier

347

$a text file $b PDF $2 rda

490

$a Handbook of Experimental Pharmacology, $x 0171-2004 ; $v 167

505

$a Protein Kinase Inhibitors for the Treatment of Disease: The Promise and the Problems -- General Aspects of PKs Inhibition -- New Design Strategies for Ligands That Target Protein Kinase-Mediated Protein-Protein Interactions -- Pharmacological Potential and Inhibitors of Individual Classes of Protein Kinases -- The Paullones: A Family of Pharmacological Inhibitors of Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3 -- Pharmacological Potential of p38 MAPK Inhibitors -- Inhibitors of PKA and Related Protein Kinases -- Inhibitors of Protein Kinase CK2: Structural Aspects -- Aminoglycoside Kinases and Antibiotic Resistance -- Pharmacological Potential and Inhibitors of Individual Classes of Protein Phosphatases -- Protein Tyrosine Phosphatases as Therapeutic Targets -- Structure-Based Design of Protein Tyrosine Phosphatase Inhibitors -- Biological Validation of the CD45 Tyrosine Phosphatase as a Pharmaceutical Target -- Serine/Threonine Protein Phosphatase Inhibitors with Antitumor Activity -- Inhibitors in Clinical Use or Advanced Clinical Trials -- Clinical Immunosuppression using the Calcineurin-Inhibitors Ciclosporin and Tacrolimus -- Targeted Therapy with Imatinib: An Exception or a Rule? -- Clinical Aspects of Imatinib Therapy -- Isoquinolinesulfonamide: A Specific Inhibitor of Rho-Kinase and the Clinical Aspect of Anti-Rho-Kinase Therapy -- Discovery and Development of Iressa: The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase.

520

$a The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkable achievements in the field and to illustrate how beneficial these studies can be for the advancement of both basic knowledge on biological regulation and deregulation and for the clinical treatment of a wide spectrum of diseases. This goal is attained by contributions of leader investigators in the field, who address the issue from different angles.

650

$a MEDICINE.

650

$a PHARMACOLOGY.

650

$a ONCOLOGY.

650

$a MEDICAL BIOCHEMISTRY.

650

$a PATHOLOGY.

650

$a Biomedicine.

650

$a Pharmacology/Toxicology.

650

$a Oncology.

650

$a Pathology.

650

$a Medical Biochemistry.

700

$a Pinna, Lorenzo A. $e editor.

700

$a Cohen, Patricia T.W. $e editor.

710

$a SpringerLink (Online service)

773

$t Springer eBooks

776

$i Printed edition: $z 9783540212423

830

$a Handbook of Experimental Pharmacology, $x 0171-2004 ; $v 167

856

$u http://dx.doi.org/10.1007/b137900

912

$a ZDB-2-SBL

950

$a Biomedical and Life Sciences (Springer-11642)

999

$a VIRTUA

No Reviews to Display

Summary	The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkable achievements in the field and to illustrate how beneficial these studies can be for the advancement of both basic knowledge on biological regulation and deregulation and for the clinical treatment of a wide spectrum of diseases. This goal is attained by contributions of leader investigators in the field, who address the issue from different angles.
Contents	Protein Kinase Inhibitors for the Treatment of Disease: The Promise and the Problems -- General Aspects of PKs Inhibition -- New Design Strategies for Ligands That Target Protein Kinase-Mediated Protein-Protein Interactions -- Pharmacological Potential and Inhibitors of Individual Classes of Protein Kinases -- The Paullones: A Family of Pharmacological Inhibitors of Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3 -- Pharmacological Potential of p38 MAPK Inhibitors -- Inhibitors of PKA and Related Protein Kinases -- Inhibitors of Protein Kinase CK2: Structural Aspects -- Aminoglycoside Kinases and Antibiotic Resistance -- Pharmacological Potential and Inhibitors of Individual Classes of Protein Phosphatases -- Protein Tyrosine Phosphatases as Therapeutic Targets -- Structure-Based Design of Protein Tyrosine Phosphatase Inhibitors -- Biological Validation of the CD45 Tyrosine Phosphatase as a Pharmaceutical Target -- Serine/Threonine Protein Phosphatase Inhibitors with Antitumor Activity -- Inhibitors in Clinical Use or Advanced Clinical Trials -- Clinical Immunosuppression using the Calcineurin-Inhibitors Ciclosporin and Tacrolimus -- Targeted Therapy with Imatinib: An Exception or a Rule? -- Clinical Aspects of Imatinib Therapy -- Isoquinolinesulfonamide: A Specific Inhibitor of Rho-Kinase and the Clinical Aspect of Anti-Rho-Kinase Therapy -- Discovery and Development of Iressa: The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase.
Subject	MEDICINE. PHARMACOLOGY. ONCOLOGY. MEDICAL BIOCHEMISTRY. PATHOLOGY. Biomedicine. Pharmacology/Toxicology. Oncology. Pathology. Medical Biochemistry.
Multimedia	http://dx.doi.org/10.1007/b137900